Waksal's gene therapy spinoff MeiraGTx says it’s time to fly with an $86M IPO
Three years after Sam Waksal’s Kadmon spun out its gene therapy tech into a startup called MeiraGTx, the New York-based biotech says it’s ready to come out to play on Nasdaq.
Waksal, an ex-con once sentenced to prison for his insider trading conviction involving Martha Stewart, had to leave Kadmon before the company was able to complete its own IPO. And now his brainchild — under the direction of former Kadmon commercial chief Alexandria Forbes — has penciled in an $86 million raise in its own S-1.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.